Stable Isotope Labelled Compounds Market Report 2021-2031

10 February 2021

Visiongain has published a new report on Stable Isotope Labelled Compounds Market Report 2021-2031: Forecasts by Type (Carbon 13, D, Oxygen 18, N15), Application (Research, Clinical Diagnostics, Industrial), End User (Pharmaceutical & Biopharmaceutical Companies, Academic institute). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

GlobalStable Isotope labelled Compounds market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031. The growth of this market is driven predominantly by the upsurge in research activities in the pharmaceutical and biotechnology sector, rising proteomics research, and the increasing pervasiveness of cancer.

Isotopic labelling is a technique used to track the passage of an isotope through a reaction metabolic pathway, or cell. The reactant is labelledby replacing specific atoms by their isotope. The reactant is then allowed to sustain the reaction. The position of the isotopes in the products is measured to determine the sequence the isotopic atom followed in the reaction or the cells metabolic passageway. The nuclides used in isotopic labelling may be stable nuclides or radionuclides. In the latter case, the labelling is called radiolabelling

COVID-19 Impact on Stable Isotope labelled Compounds Market
In this occurrence of corona virus and the threat of lives is increasing all over the world, several companies are trying hard for the better medicines and harder to get vaccines. For this process several countries are undergoing with several researches and testing. For this research processes isotope labelling is most important, so this market is getting boosted with a high speed.
Market Drivers
The growth of this market is driven majorly by the increase in research activities in the pharmaceuticals and biotechnology sector, rising proteomics research, and the rising chances of cancer, however the high cost of stable isotopes labelled compounds is expected to restrict the growth of this market.
Market Opportunities
On the basis of end users, the stable isotope labelled compounds market is classified into pharmaceutical and biotechnology companies, hospitals and diagnostic centres, academic and research institutes. But among these the pharmaceuticals and biotechnology companies will grow higher than all, owing to the upsurge in the chemicals and pharmaceuticals demand backed by huge R&D investments. This growth in-turn is directed towards the exploration of potential capability for the Isotope labelled Compounds Market.

Competitive Landscape
GlobalStable Isotope labelled Compounds market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships,acquisitions and others to increase their footprints in this market. Some of companies mentioned-PerkinElmer Inc. (US),Merck KGaA (Germany),Cambridge Isotope Laboratories, Inc. (US),URENCO Limited (UK), IsoSciences, LLC (US) ,Medical Isotopes, Inc. (US) ,Omicron Biochemicals, Inc. (US), Trace Sciences International (US), Alsachim (France), Taiyo Nippon Sanso Corporation (Japan), PerkinElmer (US), Rotem Industries Israel Ltd. (Israel), CortecNet (France, ISOFLEX (US), Huayi Isotopes Co(Canada) Mesbah Energy Co. (Iran), Shanghai Research Institute Of Chemical Industry (China), 3C Molecular, Inc. (US), C/D/N/ Isotope Inc. (Canada), Shoko Co. Ltd. (Japan).

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021


Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021


Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021


Visiongain Publishes Antiviral Drugs Treatment Market Report 2021-2031

Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral drugs R&D is driving the market growth; and rising strategic initiatives for anti-viral drugs market is another major factor propelling the market growth worldwide are some of the major factors that propel the global antiviral drugs treatment market growth.

28 April 2021